FDA Approves Trodelvy for Metastatic TNBC

Options

Have you been diagnosed with metastatic triple-negative breast cancer that has stopped responding to at least two previous treatments? On April 22, 2020, the FDA granted accelerated approval to Trodelvy (chemical name: sacituzumab govitecan-hziy) to treat adults diagnosed with triple-negative disease.

Read the breaking news story here, and comment with your thoughts below.

Read more about Trodelvy (chemical name: sacituzumab govitecan-hziy).

Categories